New Blood Test Can Detect Prostate Cancer More Accurately And Earlier

New Blood Test Can Detect Prostate Cancer More Accurately And Earlier.
A untrodden blood check-up to spot a cluster of specific proteins may point out the presence of prostate cancer more accurately and earlier than is now possible, new research suggests. The test, which has thus far only been assessed in a captain study, is 90 percent accurate and returned fewer false-positive results than the prostate definitive antigen (PSA) test, which is the current clinical standard, the researchers added. Representatives of the British companionship that developed the test, Oxford Gene Technology in Oxford, presented the findings Tuesday at the International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Denver, hosted by the American Association for Cancer Research.

The analysis looks for auto-antibodies for cancer, like to the auto-antibodies associated with autoimmune diseases such as font 1 diabetes, rheumatoid arthritis and lupus. "These are antibodies against our own proteins," explained John Anson, Oxford's defect president of biomarker discovery. "We're demanding to look for antibodies generated in the original stages of cancer. This is an exquisitely sensitive mechanism that we're exploring with this technology".

Such a investigation generates some excitement not only because it could theoretically detect tumors earlier, when they are more treatable, but auto-antibodies can be "easily detected in blood serum. It's not an invasive technique. It's a open blood test". The researchers came up with groups of up to 15 biomarkers that were backsheesh in prostate cancer samples and not present in men without prostate cancer. The assay also was able to differentiate actual prostate cancer from a more benign condition.

Because a unequivocal is currently pending, Anson would not list the proteins included in the test. "We are accepted on to a much more exhaustive follow-on study. At the moment, we are taking over 1,800 samples, which includes 1,200 controls with a full range of 'interfering diseases' that men of 50-plus are prone to and are running a very large analytical validation study".